DK0975347T3 - Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister - Google Patents

Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister

Info

Publication number
DK0975347T3
DK0975347T3 DK98913584T DK98913584T DK0975347T3 DK 0975347 T3 DK0975347 T3 DK 0975347T3 DK 98913584 T DK98913584 T DK 98913584T DK 98913584 T DK98913584 T DK 98913584T DK 0975347 T3 DK0975347 T3 DK 0975347T3
Authority
DK
Denmark
Prior art keywords
agonists
adenylate cyclase
guanyl
cyclist
synergistic combination
Prior art date
Application number
DK98913584T
Other languages
English (en)
Inventor
Rolf Beume
Dieter Flockerzi
Christian Schudt
Klaus-Dieter Beller
Friedrich Grimminger
Norbert Suttorp
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of DK0975347T3 publication Critical patent/DK0975347T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98913584T 1997-02-28 1998-02-24 Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister DK0975347T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19708049 1997-02-28
PCT/EP1998/001047 WO1998037894A1 (de) 1997-02-28 1998-02-24 Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten

Publications (1)

Publication Number Publication Date
DK0975347T3 true DK0975347T3 (da) 2008-06-16

Family

ID=7821764

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98913584T DK0975347T3 (da) 1997-02-28 1998-02-24 Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister

Country Status (12)

Country Link
US (1) US6333354B1 (da)
EP (1) EP0975347B1 (da)
JP (2) JP2001513097A (da)
AT (1) ATE386531T1 (da)
AU (1) AU6823098A (da)
CY (1) CY2607B2 (da)
DE (1) DE59814173D1 (da)
DK (1) DK0975347T3 (da)
ES (1) ES2302350T3 (da)
PT (1) PT975347E (da)
SI (1) SI0975347T1 (da)
WO (1) WO1998037894A1 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222613T3 (es) * 1997-09-12 2005-02-01 Pharis Biotec Gmbh Composicion para la terapia de diabetes mellitus y de la obesidad.
TR200100500T2 (tr) * 1998-08-26 2001-06-21 Smithkline Beecham Corporation Pulmoner hastalıkların tedavisi için terapiler
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
CA2378257A1 (en) * 1999-08-10 2001-02-15 William E. Sponsel Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
CZ302882B6 (cs) * 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
SK17052002A3 (sk) 2000-06-05 2003-12-02 Altana Pharma Ag Pyridazinónové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
DE10061137B4 (de) * 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
WO2003032964A2 (en) * 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
AU2002361417A1 (en) * 2001-12-17 2003-06-30 Altana Pharma Ag Use of selective PDE5 inhibitors for treating partial and global respiratory failure
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
WO2003086373A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US20050118715A1 (en) * 2002-04-12 2005-06-02 Hariri Robert J. Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20040087653A1 (en) * 2002-05-16 2004-05-06 Manning Pamela T. Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
CN1652843A (zh) * 2002-05-16 2005-08-10 法玛西雅公司 使用选择性iNOS抑制剂治疗呼吸系统疾病和病症
KR20050043923A (ko) * 2002-09-16 2005-05-11 알콘 매뉴팩츄어링, 리미티드 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도
PL216752B1 (pl) * 2002-11-27 2014-05-30 Nycomed Gmbh Środek leczniczy do zapobiegania objawom lub do leczenia chorób dróg oddechowych u ludzi i zastosowanie
ME00488B (me) * 2002-11-27 2011-10-10 Astrazeneca Ab Sinergička kombinacija koja uključuje roflumilast i (r,r)-formoterol
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
KR101227626B1 (ko) 2003-01-28 2013-02-01 아이언우드 파마슈티컬스, 인코포레이티드 위장병 치료 방법 및 위장병 치료용 조성물
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
DK2366393T3 (da) 2005-04-19 2013-10-21 Takeda Gmbh Roflumilast til behandlingen af pulmonal hypertension
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2268279A1 (en) * 2008-03-24 2011-01-05 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl¨-3-oxoisoindoline-4-yl}carboxamide
WO2010019450A2 (en) * 2008-08-09 2010-02-18 Nyles Bauer Synergizing active compounds for treating inflammation and other conditions
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ES2735992T3 (es) 2013-04-12 2019-12-23 Ardelyx Inc Compuestos de unión a NHE3 y procedimientos para inhibir el transporte de fosfatos
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
CN106333953A (zh) * 2015-07-08 2017-01-18 珠海津之敦医药科技有限公司 尤克那非新用途
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
WO2020186235A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3405181A1 (de) * 1984-02-10 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH01153634A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 吸入剤
IT1239281B (it) * 1989-10-27 1993-10-19 Indena Spa Composizioni per la riduzione dei depositi di grasso superfluo a base di principi attivi di origine vegetale ad attivita' agonista dell'adenilato ciclasi o/e ad attivita' antifosfodiesterasica
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
US5602110A (en) 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis

Also Published As

Publication number Publication date
PT975347E (pt) 2008-05-23
AU6823098A (en) 1998-09-18
JP2001513097A (ja) 2001-08-28
US6333354B1 (en) 2001-12-25
DE59814173D1 (de) 2008-04-03
WO1998037894A1 (de) 1998-09-03
ATE386531T1 (de) 2008-03-15
EP0975347B1 (de) 2008-02-20
ES2302350T3 (es) 2008-07-01
SI0975347T1 (sl) 2008-08-31
CY2607B2 (en) 2010-04-28
EP0975347A1 (de) 2000-02-02
JP2009073853A (ja) 2009-04-09

Similar Documents

Publication Publication Date Title
DK0975347T3 (da) Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister
BR9909677A (pt) Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas
NO20083175L (no) Synergistisk analgetisk kombinasjon av opioid analgetikum og cyklooksigenase-2 inhibitor
DK0735868T3 (da) Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
ATE332129T1 (de) Behandlung der akne mit lipoxygenase inhibitoren
DK0800514T3 (da) Substituerede imider som TNF inhibitorer
KR870005637A (ko) 약물 데포
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA199800633A1 (ru) Новые замещенные производные имидазола
DK0957914T4 (da) Formulering af 5-HT-agonister
TR199801419T2 (xx) S�lfone amino asit t�revleri ve ayn� i�erikte metaloproteinez �nleyicileri.
DE69931908D1 (de) Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
YU81991A (sh) Sinergističke terapeutske kompozicije i postupci
EA200100687A1 (ru) Комбинированная химиотерапия
FI972492A0 (fi) Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina
NO20051170L (no) Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier
CO4900022A1 (es) Composicion topica y metodo para incrementar la sintesis de la barrera del lipido la barrera de lipido utilizando dicha composicion
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
BR0113321A (pt) Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i
ES2138595T3 (es) Inhibidores de citoquinas.
Rubanyi et al. Effect of cilazapril and indomethacin on endothelial dysfunction in the aortas of spontaneously hypertensive rats
IT1264630B1 (it) Protezione antigrippaggio perfezionata per giunti particolarmente adatta nel campo petrolifero
SE8206967D0 (sv) Vantskruv
WO2000048583A3 (en) Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
FI962369A7 (fi) Farmaseuttinen formulointi myrkytyksen ehkäisemiseksi tai esihoidoksi organofosforisilla koliiniesteraasi-inhibiittoreilla